Datroway

Active Ingredient(s): Datopotamab Deruxtecan-dlnk
FDA Approved: * January 17, 2025
Pharm Company: * DAIICHI SANKYO INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Datroway 100 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 65597-801
Labeler:
Daiichi Sankyo Inc.